BioAegis’ Novel Host-Directed Human Protein for Inflammatory Disease Targeted for Growth in 2022

BioAegis Therapeutics presents its achievements in 2021 and its outlook for 2022

NORTH BRUNSWICK, NJ, Jan. 24, 2022 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a private, clinical-stage company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, reports highlights from its recent shareholder meeting.

Highlights include:

  • Expanded patent portfolio: The Company has filed additional patents to add to the more than 40 patents issued for coverage of inflammatory diseases, infections, kidney failure and neurological diseases.

Susan Levinson, PhD, CEO of BioAegis Therapeutics said: “Proud of our team’s very significant accomplishments this year, I look forward to an exciting 2022 demonstrating the value of gelsolin treatment for patients with inflammatory diseases.”

About BioAegis
BioAegis Therapeutics Inc. is a clinical-stage private company based in New Jersey whose mission is to leverage a key component of the body’s innate immune system, gelsolin, to prevent the adverse effects of diseases caused by inflammation and infection. BioAegis’ platform is based on the recombinant form of plasma gelsolin, an abundant human protein highly conserved in healthy individuals. Its role is to maintain localized inflammation at the site of injury and stimulate the body’s ability to eliminate pathogens., but normal levels are depleted by various inflammatory conditions. Restoring gelsolin levels with the recombinant human form helps immune cells fight infection and control inflammation so it doesn’t spread and cause damage.

BioAegis is the exclusive licensee of extensive worldwide intellectual property through Harvard-Brigham and Women’s Hospital. It holds more than 40 issued patents for coverage of infections, inflammatory diseases, kidney failure, multiple sclerosis and other neurological diseases. BioAegis will also have biologics exclusivity in the United States and has recently filed new intellectual property in areas of unmet need.

Investor requests:
Steven Cordovano
203-952-6373
scordovano@bioaegistx.com

Media inquiries:
Christine Lagana
clagana@bioaegistx.com

This press release contains express or implied forward-looking statements, which are based on management’s current expectations. These statements relate to, among other things, our expectations regarding management’s plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these statements. prospective. BioAegis undertakes no obligation to update any forward-looking statements in this press release as circumstances change or otherwise, and such statements speak only as of the date they are made.

Irene B. Bowles